NeoPhore secures £21.5m in Series B financing
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the completion of its £21.5m Series B financing, with a £6m financing extension. The company is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch repair (MMR) pathway to treat cancer. The additional funding will be used to progress NeoPhore’s […]